Testosterone Cypionate: Renal Protection or Renal Risk?

What Does Testosterone Cypionate Actually Do to the Kidneys?

Testosterone cypionate is an esterified androgen that hydrolyzes to free testosterone after intramuscular injection, sustaining serum levels for 7 to 14 days. Its renal effects are not a single action but a matrix of competing pathways that depend heavily on dose, baseline kidney function, comorbidities, and duration of exposure.

At replacement doses targeting serum testosterone of 400 to 700 ng/dL, the predominant renal signals are anti-inflammatory and vasodilatory. At doses used in non-medical bodybuilding contexts (sometimes 10 to 100 times the therapeutic range), the dominant signals are glomerular hypertension, podocyte injury, and proteinuria.

Androgen Receptors in Renal Tissue

Androgen receptors (AR) are expressed throughout the nephron, including the proximal tubule, glomerular mesangial cells, and podocytes [1]. Binding of testosterone to AR in the proximal tubule modulates sodium-hydrogen exchanger 3 (NHE3) activity, which affects tubular sodium reabsorption and, secondarily, glomerular filtration pressure. In animal models, AR activation in podocytes appears to attenuate podocyte apoptosis under oxidative stress conditions, though this finding has not been directly replicated in human biopsy studies [2].

The Erythropoiesis-Kidney Axis

Testosterone stimulates erythropoietin (EPO) secretion from peritubular interstitial cells in the kidney. This is the same tissue that produces EPO in response to hypoxia. At standard TRT doses, hematocrit rises by an average of 3 to 7 percentage points within 3 to 6 months [3]. That rise is generally benign in men without pre-existing erythrocytosis. In men with stages 3 to 4 CKD who often have anemia of chronic kidney disease, this EPO-stimulating effect may reduce the need for exogenous erythropoiesis-stimulating agents (ESAs), which is one mechanism through which TRT has been proposed to benefit the kidneys indirectly.

The T-Trials: What the Best Randomized Data Show

The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016, remain the highest-quality randomized evidence base for TRT in older men [4]. The consortium enrolled 790 men aged 65 or older with a serum testosterone below 275 ng/dL across seven coordinated trials, with the sexual function, physical function, and vitality trials as the primary arms.

Design and Primary Outcomes

Participants were randomized to testosterone gel 1% titrated to achieve serum levels of 500 ng/dL (approximately equivalent in systemic exposure to testosterone cypionate 100 mg IM every 2 weeks) or matching placebo for 12 months. Sexual function, walking distance in the 6-minute walk test, and vitality all improved significantly in the testosterone group (P<0.001 for sexual function; P = 0.03 for walking distance) [4].

Renal Outcomes in the T-Trials

The T-Trials were not powered or designed to evaluate renal endpoints as primary outcomes, so no dedicated eGFR analysis was pre-specified. Adverse event reporting did not identify a signal for acute kidney injury or accelerated CKD progression in the testosterone arm at 12 months [4]. Hematocrit elevation above 54% occurred in 5.9% of testosterone-treated men versus 1.0% of placebo-treated men, and that polycythemia is the most direct renal-adjacent safety concern because hyperviscosity can reduce renal perfusion.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest that clinicians evaluate hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, we suggest stopping therapy until hematocrit decreases to a safe level, to exclude hypoxia and sleep apnea as contributing causes, and to reinitiate therapy at a reduced dose." [5]

Anabolic Steroid Nephropathy: A Distinct and Serious Entity

Anabolic steroid nephropathy (ASN) is not a risk confined to testosterone cypionate at prescription doses. It is a well-documented pathological entity in people using androgens at supraphysiologic doses, typically in the context of non-medical performance enhancement.

Focal Segmental Glomerulosclerosis and Biopsy Evidence

Case series and cohort studies have documented focal segmental glomerulosclerosis (FSGS) in anabolic steroid users. A 2015 series published in the Journal of the American Society of Nephrology described 10 bodybuilders with biopsy-proven FSGS who had used androgens at doses ranging from 700 mg to 2,100 mg of testosterone-equivalent per week for 5 to 20 years [6]. For context, standard TRT with testosterone cypionate uses 100 to 200 mg per week. These individuals had a mean proteinuria of 3.0 g/day and a mean eGFR of 48 mL/min/1.73m² at presentation.

Mechanisms Driving Glomerular Injury at High Doses

Three mechanisms converge at supraphysiologic androgen concentrations:

1. Glomerular hypertrophy. Androgens increase lean body mass, and greater muscle mass raises the metabolic demand placed on the kidney. Glomerular hyperfiltration follows, with a compensatory rise in single-nephron GFR that eventually drives glomerular scarring over years [7].

2. Direct podocyte toxicity. At high androgen concentrations, AR overstimulation may disrupt podocyte cytoskeletal integrity, contributing to foot-process effacement and the histological picture of FSGS [6].

3. Dyslipidemia-mediated endothelial injury. Supraphysiologic doses suppress HDL cholesterol by 20 to 50%, promote LDL oxidation, and accelerate glomerular endothelial damage through a pathway analogous to diabetic nephropathy [8].

Does Recovery Occur After Cessation?

Partial recovery of eGFR has been reported after androgen cessation. In the JASN series, six of ten patients showed improvement in proteinuria after stopping androgens, though none achieved complete remission [6]. Mean follow-up eGFR remained below 60 mL/min/1.73m² in most patients. Persistent proteinuria above 1 g/day at 24 months after cessation was associated with progression to end-stage renal disease in two patients in that cohort.

Testosterone Cypionate in Men With Pre-Existing CKD

Men with CKD stages 1 to 5 have disproportionately high rates of hypogonadism. A cross-sectional analysis of 3,176 men in the NHANES 2011 to 2016 cycle found that men with an eGFR below 60 mL/min/1.73m² were 2.1 times more likely to have a serum testosterone below 300 ng/dL compared with men with normal kidney function [9]. That relationship has prompted interest in whether correcting hypogonadism in CKD patients confers renal benefit.

Potential Benefits in CKD Populations

Several small randomized trials and retrospective cohorts have examined TRT in men with CKD stages 3 to 4:

• A 2019 randomized controlled trial (N=100) published in the Journal of Urology assigned hypogonadal men with CKD stage 3 to testosterone undecanoate 1,000 mg every 12 weeks or placebo for 36 months [10]. The testosterone group showed a mean eGFR stabilization at 42.3 mL/min/1.73m² versus a decline to 37.1 mL/min/1.73m² in the placebo group (P = 0.04), alongside significant reductions in inflammatory markers including CRP (from 3.1 to 1.8 mg/L in the testosterone arm).

• Testosterone's anti-inflammatory actions are partly mediated through suppression of NF-kB signaling in renal tubular epithelial cells, a pathway activated by uremic toxins in CKD [2].

Risks Amplified by Reduced Kidney Function

Despite the potential benefits, CKD alters the risk-benefit calculation in important ways. Fluid retention from testosterone's aldosterone-like sodium reabsorption effects may worsen volume overload in CKD stages 4 to 5, where capacity to excrete a sodium load is already compromised. Hematocrit elevation poses a greater thrombotic risk in CKD patients who already have a prothrombotic state from uremia and dyslipidemia. And the pharmacokinetics of testosterone cypionate are not substantially altered by CKD itself (it is hepatically metabolized), but the downstream effects on volume and erythropoiesis are amplified [3].

HealthRX Risk-Stratified TRT Framework for Men With CKD

| CKD Stage | eGFR (mL/min/1.73m²) | TRT Feasibility | Key Monitoring Add-ons | |-----------|----------------------|-----------------|------------------------| | 1 to 2 | 60 to 89 / above 90 | Appropriate with standard monitoring | Annual uACR, hematocrit at 3 months | | 3a, 3b | 30 to 59 | Appropriate with enhanced monitoring | uACR every 6 months, cystatin C at baseline, BP log | | 4 | 15 to 29 | Proceed with nephrology co-management | Monthly BP and weight, hematocrit q8 weeks, avoid dose escalation | | 5 / Dialysis | <15 / ESRD | Individualized; benefit may outweigh risk in select dialysis patients | Nephrology-directed; monitor fluid balance weekly |

Fluid Retention and Blood Pressure: The Underappreciated Renal Risk

Testosterone promotes renal sodium retention through at least two mechanisms: direct activation of the mineralocorticoid receptor at high androgen concentrations, and stimulation of the renin-angiotensin-aldosterone system (RAAS). In men with normal kidney function, the resulting weight gain of 1 to 3 kg within the first 4 to 8 weeks is largely benign [4]. In men with hypertension or CKD, this sodium retention may increase both systolic blood pressure and proteinuria.

Blood Pressure Data From Controlled Trials

A meta-analysis of 11 randomized controlled trials (total N=1,544) published in the Journal of Hypertension in 2021 found that TRT at therapeutic doses produced a mean systolic blood pressure change of +1.7 mmHg (95% CI: -0.3 to +3.7 mmHg), a difference that was not statistically significant but was directionally consistent across studies [11]. The signal was larger in trials that included men with pre-existing hypertension (mean +3.2 mmHg in that subgroup).

The American Heart Association's 2023 Scientific Statement on cardiovascular effects of testosterone therapy noted: "The hemodynamic effects of testosterone, including changes in blood pressure, erythropoiesis, and sodium retention, require careful monitoring, particularly in patients with pre-existing renal or cardiovascular disease." [12]

Practical Implications

A systolic increase of 3 mmHg in a man with CKD stage 3 and a baseline systolic of 135 mmHg may push him into a range associated with faster GFR decline. Blood pressure should be measured at every visit during the first 6 months of TRT, and RAAS blockade (ACE inhibitor or ARB) should be considered or continued in men with proteinuric CKD starting TRT.

Monitoring Protocol: What to Measure and When

Proper monitoring converts testosterone cypionate from a potentially harmful drug into a manageable one. The Endocrine Society 2018 guideline provides the backbone; the additions below reflect nephrology-specific considerations [5].

Baseline Assessment (Before First Injection)

• Serum testosterone (total and free), LH, FSH to confirm hypogonadism
• Complete blood count, hematocrit
• Comprehensive metabolic panel including creatinine and estimated GFR (using CKD-EPI equation)
• Urine albumin-to-creatinine ratio (spot urine)
• Blood pressure (seated, after 5 minutes of rest)
• PSA if age 40 or older
• Lipid panel (supraphysiologic androgen use suppresses HDL)

First 6 Months of Therapy

• Serum testosterone trough at 2 weeks after first injection, then at 6 to 8 weeks after dose stabilization
• Hematocrit at 3 months and 6 months
• Creatinine and blood pressure at 3 months
• uACR at 6 months (earlier if baseline uACR was elevated)

Ongoing Annual Monitoring

Once stable, annual monitoring covers the full baseline panel. Men with CKD stage 3 or above, or with a uACR above 30 mg/g, should have creatinine and uACR checked every 6 months rather than annually.

Cystatin C deserves specific mention. Standard serum creatinine overestimates kidney function in men with high muscle mass, which is precisely the population where TRT is often used. Cystatin C is not affected by muscle mass and provides a more accurate eGFR in this context [13]. The KDIGO 2022 guideline recommends confirmatory cystatin C-based eGFR when serum creatinine-based eGFR alone would change clinical management [14].

Special Populations: Dialysis, Transplant, and Nephrotic Syndrome

Dialysis Patients

Men on hemodialysis have testosterone levels averaging 40 to 60% below age-matched controls without kidney disease, driven by uremic suppression of the hypothalamic-pituitary-gonadal axis [9]. Small trials suggest TRT in dialysis patients may improve anemia, nutritional status, and quality of life without worsening residual kidney function (which is typically negligible at this stage). Fluid balance monitoring is the primary safety concern.

Kidney Transplant Recipients

Testosterone cypionate is not contraindicated after kidney transplantation, but drug interactions with calcineurin inhibitors (tacrolimus, cyclosporine) warrant attention. Testosterone may modestly increase tacrolimus levels through CYP3A4 competition; tacrolimus trough levels should be rechecked 4 weeks after initiating TRT [15].

Nephrotic Syndrome

Active nephrotic syndrome with heavy proteinuria represents a relative contraindication to TRT initiation. Testosterone's sodium-retaining effects can worsen edema significantly, and the thrombotic risk of nephrotic syndrome (already elevated by urinary loss of anticoagulant proteins) is compounded by testosterone's pro-thrombotic effects at higher hematocrit levels.

Putting the Evidence Together: Who Benefits and Who Is at Risk?

The renal story for testosterone cypionate is genuinely dose-dependent and context-dependent. Three patient profiles summarize the current evidence:

Profile 1: Hypogonadal man, no CKD, no polycythemia risk. Testosterone cypionate at standard doses (100 to 200 mg every 1 to 2 weeks, targeting 400 to 700 ng/dL) poses minimal renal risk. The EPO-stimulating effect is modest and managed with hematocrit monitoring. No credible evidence supports that TRT at these doses causes CKD in men with normal baseline kidney function.

Profile 2: Hypogonadal man, CKD stages 3 to 4. The 2019 RCT data suggest eGFR stabilization is possible, and the anemia benefit may reduce ESA exposure. Close monitoring of fluid status, blood pressure, and uACR every 6 months is required. Nephrology co-management at stage 4 is standard of care.

Profile 3: Non-medical supraphysiologic androgen use. The risk of FSGS, proteinuria, and CKD progression is real and documented. Doses above 500 mg testosterone-equivalent per week sustained over years are associated with biopsy-proven glomerulosclerosis. The 2015 JASN series showed only partial recovery after cessation in most patients.